Immunome’s Discovery Engine leverages the information stored in memory B cells to guide the discovery of first-in-class antibody therapeutics directed at potentially novel targets in oncology and other areas.

We designed the TFF method to eliminate that problem. The technology generates millimeter-sized droplets that, because of their large size, minimize protein exposure to air–liquid interfaces. Thus, we have observed far less denaturation

Selecta Biosciences and Sobi have laid down a marker in their attempt to challenge Horizon for the gout market, delivering phase 3 data that suggest their SEL-212 candidate can match the efficacy of Krystexxa despite being administered less frequently.

Meanwhile, David Fontana, chief operating officer (COO) at immuno-oncology company Umoja Biopharma, cited Umoja’s partnership with Lupagen as a good example of two companies leveraging each other’s resources, as well as expertise. Last year, the two companies announced a collaboration to evaluate extracorporeal in vivo delivery as a route of administration for Umoja’s VivoVec particles utilizing Lupagen’s Side CAR-T delivery system.

Elixirgen is developing what it calls self-replicating RNA therapies to treat telomere biology disorders and other conditions.

Flagship Pioneering plucked Michael Severino, M.D. away from AbbVie to run point at Tessera, a startup it’s backed to pioneer a new category of genetic medicine it calls gene writing.

Aphaia continues to create additional bead formulations to broaden its product portfolio to potentially enhance treatment efficacy for other metabolic diseases and patient populations in the future.

Ashvattha Therapeutics announced that the first patient has been enrolled in a phase 1/2 study to evaluate the ability of an imaging agent to cross the blood-brain barrier and target key markers of neuroinflammation.